All News

A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.

Patient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Study finds social determinants of health linked to variations in cervical cancer rates.

The survival benefit with dostarlimab/chemotherapy was deemed unprecedented in patients with microsatellite instability high primary advanced or recurrent endometrial cancer.

Results from the KEYNOTE-868 trial showed a favorable benefit of pembrolizumab plus chemotherapy across endometrial cancer subgroups.

There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.

The ODAC meeting concluded that ide-cel showed a favorable risk/benefit profile for patients with pretreated relapsed/refractory multiple myeloma.

ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.

The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.

A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.

David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.

Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.

Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.

Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.

Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.

In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.

Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.

Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.

It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.

Targeted imaging and biopsy may accurately identify patients with breast cancer who do not have residual disease, according to Henry Kuerer, MD, PhD, FACS, CMQ.

Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.

The use of a robot to aid in nipple-sparing surgery has been a controversial topic, although ongoing trials may show its potential.

Treatment with brentuximab vedotin, lenalidomide, and rituximab yielded a progression-free survival benefit in the phase 3 ECHELON-3 trial.

Patient-reported outcomes support the clinical benefits of ide-cel among patients with relapsed/refractory multiple myeloma.

Strategies must be framed for addressing racial and geographic disparities in access for CAR T-cell and bispecific antibody therapy, according to the study authors.

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.

Investigators plan to reinitiate enrollment of patients with non-Hodgkin lymphoma as part of the phase 1a/1b NX-2127-001 trial.

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.